AWARDS
2026 – Finalist, TechConnect World 2026 Innovation Spotlights — Critical Technology Spotlights (Advanced Materials track) for BactiBlank antibiofilm coating, Raleigh, NC.
2026 – Featured PI Highlight, Provost’s TPAC-RL Spring 2026 Faculty Newsletter, University of Notre Dame.
2024- Notre Dame Integrated Imaging Facility Award for Best Imaging Publication to Kevin Armknecht of Nallathamby lab (Nanoscale Advances, 2024, 6, 1145-1162).
2024- Nanoscale Advances, 2024, 6, 1145-1162 included in the 2024 Popular Advances collection (including articles which have been very well received by the community).
2023- 1st Prize for poster in “Antimicrobial Countermeasures for Wound Infections in Military Personnel” at the 2023 Military Health System Research Symposium in Orlando, FL
2016- $1000 for prototype submission to the InnoCentive Challenge “Minimally Invasive Skin Biopsy Technique for Gene Expression Measurement” (ID 9933669)
2016- 5th Annual Harper Research Day Poster Competition prize from the Mike and Josie Harper Cancer Research Institute
2015- Pfizer Young Investigator Poster Award for the work on “Modular Assembly of Surface Functionalized Core-Shell Nanoparticles as Novel Image Contrast Agents”
2015- $3000 InnoCentive Challenge Prize for solving “Incorporating Drugs into an Exosome” (ID 9933675)
CURRENT FEDERAL AND FOUNDATION FUNDING ($1,423,830/-)
2026 – 2028 Monoclonal Antibody-Conjugated Nanoparticles for Precision CMV Antiviral Delivery NIH R21. Maria Pilar-Perez Romero (PI), P.D. Nallathamby (Co-I). 1R21AI203022-01 1 month effort
2026 – 2029 Evaluation of Novel Antibacterial Nanoparticle Therapeutics for the Treatment of Combat-Relevant Pathogens in vitro and Pre-Clinical Animal Models, DHA MID, 2 month effort + 12 months graduate student
2025 – 2027 Multispecific Bridge Nanoparticles to Engage T Cells and Off-the-Shelf CAR-T Cells Against Antigen(+) EC Tumors to Enhance Antitumor Immune Activity, CDMRP-PRCRP IDEA award (Invited) HT94252510332, 1.5 months effort, PI; Collaboration with IUSM-SB.
2024 – Current Indiana CTSI Navigator for Notre Dame Campus 2 months effort.
Externally Funded Projects Completed (Previous years):
2023 – 2024 AFM study to Elucidate Mechano-Electrical Differences in Cell Membranes of Cancer Cells and Normal Primary Cells using Magnetoelectric Nanoparticles, DOE-CNMS2022-B-01661, $0 (user facility access for instrument and CNMS PI time); PI: P.D. Nallathamby/L. Collins.
2022 – 2024 Off-the-Shelf CAR-T (uCAR-T) Cell Re-targeted to Multiple Cancer Types using Dual-Antibody, Bridge Nanoparticles and Controllable uCART Activation, CTSI-Think Tank/IU-B, $10,000; 0.05 months effort, PI; Milestone I met, applying for Phase II in vivo studies.
2021– 2022 Aptima /Sentinel/ND/Purdue “SMARTWATCH: Sensor-based Monitoring and Assessment via Remote Telemetry and Wearables for Augmentation of Tactical Care and Health”, NBMC-AFRL, $1,384,355.19; 4.2% FTE as senior personnel.
2020– 2021 P.D. Nallathamby, S. Zhang, F. Liu “Neutralizing the Cardiotoxicity of Anthracyclines”, American Cancer Society- Institutional Research Grant, $32,450, in vivo experiments.
2018- 2021 P.D. Nallathamby, S. Zhang, P. Helquist “Magnetic Nanocarrier-based, Precise Chemotherapeutic Delivery to Metastatic Cancer Cells In Vivo“, American Cancer Society- Institutional Research Grant, $30,000, in vivo experiments and 8% FTE.
2019 – 2020 P.D. Nallathamby, S.W. Lee, J. Hopf “Biomimetic Infection Reporting Antimicrobial Nanoparticles for Wound and Surgical Site Applications”, Clinical Translational Sciences Institute-Project Development Team, $20,000 in vitro/ in vivo supplies and 25% stipend post-doctoral salary.
PATENTS
2026 – U.S. Patent 12,576,160 B2 — “Dual antibody bridge nanoparticles for efficient targeting of cancer cells using immunotherapy (universal CAR-T cells) or other anticancer therapeutics.” Inventor: P.D. Nallathamby. Issued March 17, 2026 (Notice of Allowance Jan. 21, 2026); University of Notre Dame.
2024 – U.S. Patent 12,161,725 B2 — “Phage-Mimicking Nanoparticles.” Inventors: P.D. Nallathamby, J. Hopf. Licensed to nanoBLASTx, LLC via the Notre Dame IDEA Center, March 2026. Nallathamby is only the inventor and is neither affiliated with, nor working for nanoBLASTx, LLC or any other commerical entities.
Recent Comments